Project Grant R01DE033702

Award Date 9/1/24
Completion Date 8/31/29
Dollars Obligated $73K
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Louisville, KY 40202, USA
Similar Awards
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $873,546 to the University of Texas Health Science Center at Houston to develop an "oral micro-drug factory" using engineered Limosilactobacillus reuteri bacteria to secrete the anti-inflammatory cytokine interleukin-10 (IL-10) for treating periodontitis. The goal is to locally administer the...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $995,000.00 to the ADA Forsyth Institute, Inc. (doing business as The Forsyth Institute) to conduct research on the mechanisms of peroxisome proliferator-activated receptor-alpha (PPAR-α) regulation in periodontitis. The research aims to determine if PPAR-α agonist treatment can modulate macrophage polarization to...
This federal Project Grant award of $241,500.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, supports research to identify diffusible small molecules that regulate the replication of the bacterium Porphyromonas gingivalis (P. gingivalis). The research aims to establish the identity of growth-promoting cues produced by different strains of P. gingivalis and the bacterium Veillonella parvula that...
This Project Grant award of $858,000 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to explore the mechanisms by which the bacterium Veillonella inhibits the hemolytic activity of the periodontal pathogen Porphyromonas gingivalis. The research aims to: 1) investigate how Veillonella's heme production suppresses P. gingivalis' hemolysis, and 2) determine how P. gingivalis regulates...
This Project Grant award of $226,500.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to define how oral pathogens affect aging-associated immune responses and whether inhibition of the CD38 signaling pathway can attenuate inflammatory bone loss and alleviate aging-associated immune responses induced by oral pathogens. The research will be conducted by the Medical University of...
This Project Grant award of $248,627 from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121) supports research to understand the role of T cell responses to the oral pathogen Aggregatibacter actinomycetemcomitans in the immunopathology of periodontal disease. The research aims to: 1) assess systemic T cell responses to this pathogen in human periodontal disease, and 2) determine the role of...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $446,875 to support research on the role of a novel G protein-coupled receptor, MRGPRX2, in the development of periodontal disease. The funded research aims to develop two humanized mouse models to study the contribution of MRGPRX2-expressing mast cells to Porphyromonas gingivalis-induced and ligature-induced...
This Project Grant award of $398,000 from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) will support a mechanistic investigation of microbial interactions and their impact on periodontal health during clear aligner orthodontic treatment. The research will focus on the synergistic relationship between three bacterial species - Fusobacterium nucleatum, Actinomyces spp., and Saccharibacteria (TM7) - that...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), provides $645,009 to the Augusta University Research Institute, Inc. to investigate the role of osteocyte NOD1 signaling in bone loss associated with periodontal disease. The key objectives are to: 1) determine if osteocytes use the NOD1 receptor to recognize periodontal pathogens and induce the bone resorption...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will provide $423,500.00 to Nova Southeastern University, Inc. to develop a humanized mouse model of periodontitis. The goal is to investigate the potential pathogenic role of the protein Semaphorin 4D expressed by human osteoclasts in the progression of periodontal disease. This advanced mouse model will allow researchers to...

PATHOADAPTIVE MODULATION OF PORPHYROMONAS GINGIVALIS LIPOPOLYSACCHARIDE STRUCTURE AND FUNCTION - PROJECT SUMMARY PERIODONTITIS IS A POLYMICROBIAL-DRIVEN AND PREVALENT INFLAMMATORY DISEASE OF THE TISSUES SUPPORTING THE TEETH IN ADULTS. STUDIES REVEALED HIGHLY ACTIVE BIOSYNTHESIS OF THE LIPOPOLYSACCHARIDE (LPS) COMPONENTS OF THE GRAM-NEGATIVE BACTERIA, AND ALSO COMPONENTS OF CYCLIC DI-3', 5'-ADENYLIC ACID (C-DI-AMP) SECOND MESSENGER SIGNALING IN THE PERIODONTAL POCKETS OF THE PERIODONTITIS SUBJECTS. FINDINGS FROM OUR LABORATORY DEMONSTRATED, FOR THE FIRST TIME, THAT THE LPS STRUCTURE AND FUNCTION IS REGULATED BY C-DI-AMP SIGNALING IN PORPHYROMONAS GINGIVALIS (PG) STRONGLY IMPLICATED IN THE ONSET AND DEVELOPMENT OF PERIODONTITIS. OUR STUDIES INDICATE THAT C- DI-AMP REGULATION OF LPS STRUCTURE AND THEREFORE, FUNCTION, IS AN ESSENTIAL ASPECT OF THE PATHOGENESIS OF THE PERIODONTAL PATHOGENS. WE HAVE IDENTIFIED GENES ENCODING SOME OF THE KEY COMPONENTS CONSTITUTING THE C-DI- AMP SIGNALING PATHWAY IN PG, INCLUDING THE ESSENTIAL C-DI-AMP SYNTHASE GENE (DACPG; PGN_0523), THE C-DI-AMP PHOSPHODIESTERASE GENE (PDEPG; PGN_0521), AND THE PREDICTED REGULATORY GENE CDAR (PGN_1486), ALL OF WHICH REGULATE PG LPS STRUCTURE AND FUNCTION. HOWEVER, WE DO NOT YET KNOW THE MECHANISMS OF THE REGULATION OF LPS STRUCTURE AND FUNCTION BY C-DI-AMP SIGNALING AND ITS CONTRIBUTION TO THE PATHOGENESIS OF THE PERIODONTAL PATHOGENS AND PERIODONTITIS PROGRESSION. WE WILL INVESTIGATE THESE MECHANISMS IN PG IN MOLECULAR DETAIL THROUGH THESE AIMS: SPECIFIC AIM 1: WE WILL CONDUCT A COMPREHENSIVE ANALYSIS OF STRUCTURAL DIFFERENCES IN LPS SYNTHESIZED BY WT (STRAIN 381), THE STRAIN LACKING THE C-DI-AMP PHOSPHODIESTERASE GENE (PDEPG) AND A REGULATOR OF C-DI-AMP LEVELS (CDAR) MUTANTS. THIS WILL INVOLVE LARGE-SCALE LPS PURIFICATION, FOLLOWED BY CHROMATOGRAPHIC FRACTIONATION, AND THOROUGH CHARACTERIZATION OF LPS CONSTITUENTS USING FLATN, MALDI-TOF MS, AND NMR TECHNIQUES. SPECIFIC AIM 2: WE WILL DETERMINE THE PROTEIN INTERACTION NETWORK OF THE C-DI-AMP-REGULATED LPS STRUCTURE AND FUNCTION AND IDENTIFY C-DI-AMP RECEPTORS AND EFFECTORS THROUGH VARIOUS GENETIC AND BIOCHEMICAL APPROACHES. THE SIGNIFICANCE OF THE INTERACTOME WILL BE DEMONSTRATED BY CREATING MUTATIONS IN THE CORRESPONDING GENES IN PG AND DETERMINING THEIR EFFECT ON LPS STRUCTURE AND FUNCTION. SPECIFIC AIM 3: WE WILL USE HIGHLY PURE INDIVIDUAL LIPID A/LPS FRACTIONS ISOLATED FROM WT, PDEPG AND CDAR MUTANTS, PURIFIED THROUGH CHROMATOGRAPHIC FRACTIONATION, TO TEST THEIR IMMUNOSTIMULATORY ACTIVITIES IN RELATION TO THE TLR4 SIGNALING PATHWAY, THE COMPLEMENT SYSTEM, AND CYTOKINE PRODUCTION. THESE ASSESSMENTS WILL INVOLVE CELL CULTURE ASSAYS, HUMAN WHOLE BLOOD STUDIES, AND AN ANIMAL MODEL OF INFLAMMATION. UPON COMPLETION OF THE PROPOSED STUDIES, WE WILL LEARN HOW C-DI-AMP SIGNALING CONTROLS LPS STRUCTURE-FUNCTION, IMPACTS IMMUNOSTIMULATORY POTENTIAL OF LPS VARIANTS, AND SUBSEQUENTLY HOST DEFENSE RESPONSES. SINCE C-DI-AMP SIGNALING DOES NOT EXIST IN MAMMALS, OUR FINDINGS WILL INFORM ABOUT A NOVEL DRUGGABLE TARGET.

Posted 8/28/24